Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 57.43%
March 31, 2026 -18.23%
December 31, 2025 32.76%
September 30, 2025 90.64%
June 30, 2025 93.40%
March 31, 2025 87.81%
December 31, 2024 88.11%
September 30, 2024 83.36%
June 30, 2024 86.86%
March 31, 2024 76.95%
December 31, 2023 80.22%
September 30, 2023 60.38%
June 30, 2023 35.49%
March 31, 2023 91.85%
December 31, 2022 99.43%
September 30, 2022 0.00%
June 30, 2022 0.00%
March 31, 2022 0.00%
December 31, 2021 0.00%
September 30, 2021 0.00%
June 30, 2021 0.00%
March 31, 2021 0.00%
December 31, 2020 0.00%
September 30, 2020 0.00%
June 30, 2020 0.00%
Date Value
March 31, 2020 0.00%
December 31, 2019 0.00%
September 30, 2019 0.00%
June 30, 2019 0.00%
March 31, 2019 0.00%
December 31, 2018 0.00%
September 30, 2018 0.00%
June 30, 2018 0.00%
March 31, 2018 0.00%
December 31, 2017 0.00%
September 30, 2017 0.00%
June 30, 2017 0.00%
March 31, 2017 0.00%
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%
March 31, 2016 0.00%
December 31, 2015 0.00%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 0.00%
March 31, 2014 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 74.71%
Aprea Therapeutics, Inc. --
ACADIA Pharmaceuticals, Inc. 90.81%
Alnylam Pharmaceuticals, Inc. 76.88%
Savara, Inc. --

Gross Profit Margin (Quarterly) Related Metrics